Ardelyx to Participate at the Piper Sandler 35th Annual Healthcare ConferenceGlobeNewsWire • 11/21/23
XPHOZAH® (tenapanor) Granted Orphan Drug Designation by U.S. FDA for the Treatment of Pediatric HyperphosphatemiaGlobeNewsWire • 11/15/23
Ardelyx Shares Positive Data from Studies of XPHOZAH® (tenapanor), a First-in-Class Phosphate Absorption Inhibitor, at ASN Kidney Week 2023GlobeNewsWire • 11/03/23
Ardelyx Reports Third Quarter 2023 Financial Results and Updates 2023 U.S. IBSRELA® Net Sales Revenue GuidanceGlobeNewsWire • 10/31/23
Ardelyx Shares Positive Data on Symptom Response During Treatment With IBSRELA® (tenapanor) for IBS-C and hosts IBS-C Product Theater at ACG 2023GlobeNewsWire • 10/23/23
Ardelyx Announces Amendment of Debt Financing Agreement with SLR Capital Partners to Provide $50 Million of Additional Committed CapitalGlobeNewsWire • 10/17/23
FDA Approves XPHOZAH® (tenapanor), a First-in-Class Phosphate Absorption InhibitorGlobeNewsWire • 10/17/23